CN1293865C - Cell growth regulating factor R and its prepn process - Google Patents
Cell growth regulating factor R and its prepn process Download PDFInfo
- Publication number
- CN1293865C CN1293865C CNB021510873A CN02151087A CN1293865C CN 1293865 C CN1293865 C CN 1293865C CN B021510873 A CNB021510873 A CN B021510873A CN 02151087 A CN02151087 A CN 02151087A CN 1293865 C CN1293865 C CN 1293865C
- Authority
- CN
- China
- Prior art keywords
- cell growth
- arginine
- regulatory factor
- natural
- growth regulatory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000010261 cell growth Effects 0.000 title claims abstract description 28
- 230000001105 regulatory effect Effects 0.000 title claims abstract description 28
- 238000000034 method Methods 0.000 title claims description 6
- 230000008569 process Effects 0.000 title description 2
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 30
- 239000004475 Arginine Substances 0.000 claims abstract description 17
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 17
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 238000007710 freezing Methods 0.000 claims abstract description 10
- 230000008014 freezing Effects 0.000 claims abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 7
- 230000001580 bacterial effect Effects 0.000 claims description 37
- 241000894006 Bacteria Species 0.000 claims description 12
- 239000000284 extract Substances 0.000 claims description 12
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 8
- 238000001514 detection method Methods 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 12
- 238000001914 filtration Methods 0.000 abstract description 4
- 244000052616 bacterial pathogen Species 0.000 abstract description 2
- 238000011076 safety test Methods 0.000 abstract description 2
- 241001052560 Thallis Species 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000036737 immune function Effects 0.000 abstract 1
- 230000001338 necrotic effect Effects 0.000 abstract 1
- 210000001328 optic nerve Anatomy 0.000 abstract 1
- 238000007789 sealing Methods 0.000 abstract 1
- 238000007873 sieving Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 11
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 9
- 238000007689 inspection Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 230000000844 anti-bacterial effect Effects 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000008929 regeneration Effects 0.000 description 6
- 238000011069 regeneration method Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 239000012535 impurity Substances 0.000 description 5
- 239000010409 thin film Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 241000191963 Staphylococcus epidermidis Species 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000007639 printing Methods 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 206010003694 Atrophy Diseases 0.000 description 3
- 241001478240 Coccus Species 0.000 description 3
- 230000037444 atrophy Effects 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 241000304886 Bacilli Species 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 241000588722 Escherichia Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000192041 Micrococcus Species 0.000 description 2
- 241000588655 Moraxella catarrhalis Species 0.000 description 2
- 210000004460 N cell Anatomy 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 235000013580 sausages Nutrition 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 208000001992 Autosomal Dominant Optic Atrophy Diseases 0.000 description 1
- 208000004130 Blepharoptosis Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010015995 Eyelid ptosis Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010020675 Hypermetropia Diseases 0.000 description 1
- 208000010886 Peripheral nerve injury Diseases 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010041591 Spinal osteoarthritis Diseases 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 101150036080 at gene Proteins 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000036319 cervical spondylosis Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 201000007717 corneal ulcer Diseases 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000004305 hyperopia Effects 0.000 description 1
- 201000006318 hyperopia Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 230000004379 myopia Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000004273 ophthalmic nerve Anatomy 0.000 description 1
- 208000027014 optic atrophy 1 Diseases 0.000 description 1
- 208000025019 optic atrophy 2 Diseases 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 201000003004 ptosis Diseases 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000008470 skin growth Effects 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 208000005801 spondylosis Diseases 0.000 description 1
- 235000013547 stew Nutrition 0.000 description 1
- 231100000456 subacute toxicity Toxicity 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to natural cell growth regulating factor R and a preparation method thereof. The preparation method comprises the following steps: sieving Gram-positive cocci and Gram-negative cocci or bacilli, and freezing and preserving a strain; conventionally cultivating the strain at a temperature of 4 to 38 DEG C and leaving beneficial thallus fragments via filtration for at least one time to remove harmful thalli, namely extracting natural genes; adding a certain amount of arginine in the natural genes; after safety test, sealing a water agent under a GMP standard to prepare the natural cell growth regulating factor R. 1 mu g of the natural genes of the prepared natural cell growth regulating factor R can be compounded with more than 1 mu g of arginine. The natural cell growth regulating factor R can prompt a body to activate and reinforce immunological functions so as to reinforce TC, re-repair and reshape senescent, necrotic, denatured, atrophic and fiberized tissue cells, and regenerate and replant capillary vessels to make optic nerve cells re-repaired and reshaped, etc.
Description
Technical field
What the present invention relates to is a kind of medicine and preparation method that is of value to the Growth of Biologic Cell regulation and control, belongs to a kind of biological medicine.
Background technology
The mankind, birth and old age, sickness and death are a kind of natural laws, along with wearing out of human body cell, the regeneration function of its cell will be lost gradually, human body enters aging period, and the intravital various cellular degenerations of people are had an operation as the old man and to be recovered to want the slow well evidence that is mostly more than the adolescent.The aging of people mainly shows on the cell senescence and deterioration of various internal organs, thereby in recent years, the medical expert of countries in the world is attempting to study relevant " the long-lived medicine " that increases man's lifespan.So-called long-lived medicine is exactly nothing but that this medicine can promote functions such as the enhancing of the regeneration of human body cell and repair ability and improvement.Yet the file that yet there are no similar contents such as " long-lived medicines " is published.On the other hand, even if the someone does not also enter old age, but still will there be its situation about can not normally repair of necrosis of human cell tissue in the part of its human body, as cervical spondylosis patient or prolapse of lumbar intervertebral disc patient or the like.These patients are in the majority with the older, degeneration, atrophy, downright bad cell fibrosis tissue existence mainly still because taken place in the mechanism of its morbidity in the part of its human body, conventional treatment method is exactly an excision, again plantation tissue or transplanting are corresponding then organizes, this therapeutic method of surgery is passive, and do not have the positive therapeutic effect, and it can only be treated devastatingly, and its effect is not desirable.Also have a kind of skin growth factor of using to treat, but it can only play the table effect of controlling, but corium, ligament, muscle cell tissue are not had regeneration, effect such as repair and mould again, thereby what good therapeutic effect in fact they not have.
At present, the research and development of microorganism medical science is very fast, people have had darker understanding to various antibacterials and virus, as publishing in " medical microorganism " university teaching material on probation of distribution in June, 1979 by the People's Health Publisher, enumerated and introduced the kind of antibacterial and virus, and the biological character of each bacterioid or the like.Each bacterioid can be realized the technical security acceptance test to the antibacterial thalline by culture medium culturing and after filtering.In existing disclosed technical data, the content introduction of pair bacteria culture media is arranged, as sausage and sausage agar culture medium, pig heart infusion protein culture medium etc.; After the cultivation by these bacteria culture medias, the antibacterial thalline can split into the thalline material of reproductive capacity, and part cracks into the bacterial chip of no reproductive capacity simultaneously, and the antibacterial thalline also can produce secretory substance and stay culture medium complex etc. in incubation.In existing disclosed technical data, the method introduction of some aseptic filtrations is also arranged, it adopts filters such as filter membrane filter, Cai's seitz filter Seitz to realize, selects the aperture of certain filter opening and conventional filter can remove some thalline materials etc.Though at present people have had darker understanding to each bacterioid, only be confined to the category understood, there are many deficiencies to how utilizing antibacterial to carry out medical research such as preventing and treating diseases, stayed many blank spots medically.
Network address is on the Internet:
Www.ncgcf.com..cnPublished one piece of Zhejiang University's master thesis " n cell growth regulatory factor to peripheral nerve injury after the regeneration and the research of repairing " on May 25th, 2002, the 13rd page of this paper, the effective original component that discloses n cell growth regulatory factor (NCGCF) is respectively: A, gram-positive cocci through routine cultivate, the extract of conventional thin film, be used for animal experiment study after safety inspection is qualified, representative strain commonly used has: epidermis Staphylococcus albus (staphylococcus:s.epidermidis); B, Gram-negative coccus through routine cultivate, the extract of conventional thin film, be used for animal experiment study after safety inspection is qualified, representative strain commonly used has: micrococcus catarrhalis (B.catarrhalis); C, Gram-positive bacillus through routine cultivate, the extract of conventional thin film, be used for animal experiment study after safety inspection is qualified, representative strain commonly used has: non-pathogenic bacillus subtilis (B.subpilis); D, gram negative bacilli through routine cultivate, the extract of conventional thin film, be used for animal experiment study after safety inspection is qualified, representative strain commonly used has: Bacterium entericum (escherichia coli) (Escherichia); E, be used for Gram-positive, negative cocci, Gram-positive, negative bacillus and cultivate the back, mix the extract [using representative strain always is: epidermis Staphylococcus albus (staphylococcus:s.epidermidis), micrococcus catarrhalis (B.catarrhalis), non-pathogenic bacillus subtilis (B.subpilis), Bacterium entericum (escherichia coli) are (Escherichia)] of the conventional thin film in back, be used for the zoopery of this experiment after safety inspection is qualified through routine.N cell growth regulatory factor (NCGCF) has repair to tissue injury, can improve muscle and neural blood circulation, strengthens anabolic effect etc.But the inventor is used for the effective original component of this n cell growth regulatory factor (NCGCF) to find after the human experimentation: when using the effective original component of the n cell growth regulatory factor series described in the paper merely, be used for behind the human body 4-8 hour, just begin to have a fever 38 ℃ more than-39 ℃, and the local pain redness, make the effective original component product of this n cell growth regulatory factor series can not directly devote the human body use like this.
Summary of the invention
The object of the present invention is to provide and a kind of human body cell is had the adjusting and controlling growth effect, strengthen the n cell growth regulatory factor R and the preparation method of functions such as the regeneration of inside of human body cell tissue, reparation, contain natural gene, the arginine that extracts in Gram-positive, negative cocci or the bacillus among this n cell growth regulatory factor R, and the configurable arginine that has more than the 1 μ g of 1 μ g natural gene.
1 μ g natural gene disposes the arginine of 1 μ g-500mg among the described n cell growth regulatory factor R.
1 μ g natural gene disposes the arginine of 1-200mg among the described n cell growth regulatory factor R.
A kind of method of producing n cell growth regulatory factor R, it is earlier Gram-positive, negative cocci or bacillus to be screened and the freezing bacterial strain, with bacterial strain conventional cultivation under 4-38 ℃ of temperature, and after at least once removing by filter harmful bacteria, stay useful bacterial chip and promptly extract natural gene, in natural gene, quantitatively add arginine, after safety detection, water preparation or freezing dry powder close to seal and form under the GMP standard.Described useful bacterial chip, its component comprise the genetic stew of thalline, the secretions of thalline and the culture medium complex of this thalline.
Described bacterial strain is conventional the cultivation under 10--35 ℃ of temperature, and stays useful bacterial chip promptly extract natural gene after secondary filter is removed harmful bacteria at least.
The present invention is by screening removing from office blue people's positive, negative cocci or bacillus, through cultivating, filter removal impurity and harmful substance, as the thalline that causes a disease, the useful bacterial chip that extraction stays is a natural gene, so-called natural gene be meant filtrate such as useful bacterial chip routine cultivate and filter process in do not change its molecular structure and chemical physical property, thereby be natural, institute's tht gene is meant that useful bacterial chip is a kind of measurement unit of somatic cells; This useful gene pairs human body cell has the adjusting and controlling growth effect, groups of cells to necrosis is woven with reparation and shaping action more again, with its mix with arginine make the n cell growth regulatory factor after, special clinical therapeutic efficacy is arranged, both have synergism, have and better impel body to activate raise immunity, TC is strengthened, and necrosis, degeneration, atrophy, Fibrotic histiocyte are repaired again, mould again, blood capillary regeneration, grow again, thereby play the reparation again of optic cell, effect such as mould again.
N cell growth regulatory factor R of the present invention, its commodity daybreak by name is refreshing, and this medicine is to treatment ophthalmic diseases, keratitis, corneal ulcer, the ophthalmic nerve atrophy, cataract, detachment of retina, children's's myopia, old hypermetropia, blepharoptosis, the retina blood supply insufficiency, blurred vision etc. are effective in cure.Through animal safety test, acute, subacute toxicity test is negative, undue toxicity, long term toxicity test feminine gender.
Model case:
Case 1, the male, 12 years old, traumatic optic atrophy 1 year was surplus, and traditional treatment does not have produce effects, through the made medicine of the present invention---behind the refreshing Comprehensive Treatment of daybreak, vision increases to 1.0 by 0.1.
Case 2, the women, 28 years old, traumatic optic atrophy 2 years was surplus, and traditional treatment does not have produce effects, and in 6 weeks behind this medicine Comprehensive Treatment, vision is clearly better.
Case 3, women, 12 years old, deaf mute (injection of chain syphilis causes).Behind this medicine Comprehensive Treatment, take an evident turn for the better.
The specific embodiment
The present invention will be described in detail below in conjunction with embodiment: embodiment 1, earlier gram-positive cocci is screened and the freezing bacterial strain, with bacterial strain conventional cultivation under 6 ℃ of temperature, the general low more incubation time of temperature is long more, bacterial strain stays useful bacterial chip after successively removing by filter impurity and harmful bacteria four times after fully cultivating, be the extraction natural gene, because the gram coccus is a bacterial strain in spite of illness common in the clinical medicine, the public can obtain from public occasion, therefore this strain need not special preservation, and it through after cultivating fully and filtering, can be reached the purpose of removing disease carrying germ, getting useful bacterial chip is natural gene 1 μ g, quantitatively add the 1mg arginine therein, measure content and after safety detection, water preparation closes envelope and forms under the GMP standard, after product inspection is qualified, printing package.Described safety detection comprises the detection to no pathogenic bacterium; Described arginine is a kind of of amino acids, and it also is common a kind of biochemical product, and the public also can obtain on a public occasion easily.
Embodiment 2, earlier Gram-negative coccus is screened and the freezing bacterial strain, with bacterial strain conventional cultivation under 12 ℃ of temperature, bacterial strain stays useful bacterial chip after successively removing by filter impurity and harmful bacteria three times after fully cultivating, be the extraction natural gene; Getting useful bacterial chip is natural gene 1 μ g, quantitatively adds the 3mg arginine therein, measures content and after safety detection, water preparation closes envelope and forms n cell growth regulatory factor R under the GMP standard, after product inspection is qualified, and printing package.
Embodiment 3, earlier gram negative bacilli is screened and the freezing bacterial strain, with bacterial strain conventional cultivation under 20 ℃ of temperature, bacterial strain stays useful bacterial chip after removing impurity and harmful bacteria through the priority secondary filter after the abundant cultivation, be the extraction natural gene; Getting useful bacterial chip is natural gene 1 μ g, quantitatively adds the 8mg arginine therein, measures content and after safety detection, water preparation or freezing dry powder close envelope and form n cell growth regulatory factor R under the GMP standard, after product inspection is qualified, and printing package.
Embodiment 4, earlier Gram-positive bacillus is screened and the freezing bacterial strain, with bacterial strain conventional cultivation under 38 ℃ of temperature, bacterial strain stays useful bacterial chip through after once removing by filter impurity and harmful bacteria after fully cultivating, be the extraction natural gene, it is many more normally to filter number of times, left＜extract useful bacterial chip be that natural gene is just pure more.Getting useful bacterial chip is natural gene 1 μ g, quantitatively adds the 20mg arginine therein, measures content and after safety detection, water preparation closes envelope and forms n cell growth regulatory factor R under the GMP standard, after product inspection is qualified, and printing package.
Other embodiments of the invention all can dispose 1 μ g at gene 1 μ g---arbitrarily configuration in the arginic scope of 500mg.
Claims (4)
1, a kind of cell growth regulatory factor R, it is characterized in that containing the natural gene that extracts in Gram-positive, negative cocci or the bacillus among this n cell growth regulatory factor R, also contain arginine, wherein 1 μ g natural gene disposes the arginine of 1 μ g-500mg.
2, cell growth regulatory factor R according to claim 1 is characterized in that among the described n cell growth regulatory factor R, 1 μ g natural gene disposes the arginine of 1-200mg.
3, a kind of method of producing cell growth regulatory factor R as claimed in claim 1 or 2, it is earlier Gram-positive, negative cocci or bacillus to be screened and the freezing bacterial strain, with bacterial strain conventional cultivation under 4-38 ℃ of temperature, and after at least once removing by filter harmful bacteria, stay useful bacterial chip and promptly extract natural gene, in natural gene, quantitatively add arginine, after safety detection, water preparation or freezing dry powder close to seal and form under the GMP standard.
4, the method for producing cell growth regulatory factor R according to claim 3 is characterized in that described bacterial strain conventional cultivation under 10-35 ℃ of temperature, and stays useful bacterial chip promptly extract gene after secondary filter is removed harmful bacteria at least.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021510873A CN1293865C (en) | 2002-12-06 | 2002-12-06 | Cell growth regulating factor R and its prepn process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021510873A CN1293865C (en) | 2002-12-06 | 2002-12-06 | Cell growth regulating factor R and its prepn process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1506056A CN1506056A (en) | 2004-06-23 |
| CN1293865C true CN1293865C (en) | 2007-01-10 |
Family
ID=34234249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021510873A Expired - Fee Related CN1293865C (en) | 2002-12-06 | 2002-12-06 | Cell growth regulating factor R and its prepn process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1293865C (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1044468A (en) * | 1989-01-28 | 1990-08-08 | 杭州市第三人民医院 | Cell growth stimulant and manufacture method thereof |
-
2002
- 2002-12-06 CN CNB021510873A patent/CN1293865C/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1044468A (en) * | 1989-01-28 | 1990-08-08 | 杭州市第三人民医院 | Cell growth stimulant and manufacture method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1506056A (en) | 2004-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100347289C (en) | Bacillus subtilis, method for preparing bacillus subtilis and its using method | |
| CN1293865C (en) | Cell growth regulating factor R and its prepn process | |
| CN1293875C (en) | Cell growth regulatnig factor S and its prepn process | |
| CN1293866C (en) | Cell growth regulating factor II and its prepn process | |
| CN1241575C (en) | Cell growth regulating factor U and its prepn process | |
| CN1323669C (en) | Cell growth regulating factor P and its prepn process | |
| CN1235594C (en) | Cell growth regulating factor Q and its prepn process | |
| CN1235593C (en) | Regulatary factor T for cell growth, and its prepn. method | |
| CN1323670C (en) | Cell growth regulatory factor L and preparing process thereof | |
| CN1263459C (en) | Cell growth regulating factor O and its prepn process | |
| CN1263460C (en) | Cell growth regulating factor G and its prepn process | |
| CN1263461C (en) | Cell growth regulatnig factor F and its prepn process | |
| CN1305465C (en) | Cell growth regulating factor I and its prepn process | |
| CN1233328C (en) | Cell growth regulating factor K and its prepn process | |
| CN1323671C (en) | Cell growth regulating factor J and its prepn process | |
| CN1323672C (en) | Cell growth regulatory factor C and preparing process thereof | |
| CN1255113C (en) | Cell growth regulating factor D and its prepn process | |
| CN1255112C (en) | Cell growth regulating factor E and its prepn process | |
| CN1245164C (en) | Cell growth regulating factor oral liquid and its prepn process | |
| CN100360185C (en) | Preparation method of medicine for treating pelada | |
| CN1506052A (en) | Cell growth regulating factor X and its prepn process | |
| CN1424045A (en) | Cell growth regulating factor B and preparation thereof | |
| CN1421211A (en) | Cell growth regulating factor M and its prepn process | |
| CN1435185A (en) | Cell growth regulatory factor A and preparing process thereof | |
| CN1506053A (en) | Cell growth regulating factor W and its prepn process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| PP01 | Preservation of patent right | ||
| PP01 | Preservation of patent right |
Effective date of registration: 20171101 Granted publication date: 20070110 |
|
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: Xie Xuming Document name: Notice of preservation procedure |
|
| PD01 | Discharge of preservation of patent | ||
| PD01 | Discharge of preservation of patent |
Date of cancellation: 20200122 Granted publication date: 20070110 |
|
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: Xie Xuming Document name: Notification of Termination of Procedure |
|
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: Xie Xuming Document name: payment instructions |
|
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: Xie Xuming Document name: Notice of termination of patent right |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070110 Termination date: 20201206 |